US FDA lifts import alert imposed on Sun Pharma's Mohali facility

Move clears the way for supply of products from Mohali facility to the US market

Sun Pharma extends savings card program for cancer drug in US

Premium

BS B2B Bureau Mumbai

Last Updated : Mar 14 2017 | 4:28 PM IST

The US Food & Drug Administration (FDA) will lift the import alert imposed on Sun Pharma’s Mohali (Punjab) manufacturing facility and remove the facility from the Official Action Initiated (OAI) status. This proposed action will clear the path for Sun Pharma to supply approved products from the Mohali facility to the US market, subject to normal US FDA regulatory requirements.

The Mohali facility was inherited by Sun Pharma as part of its acquisition of Ranbaxy Laboratories Ltd in 2015. The US FDA had taken action against the Mohali facility in 2013 when it ordered the facility to be fully subject to

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in